Trial Profile
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2022
Price :
$35
*
At a glance
- Drugs Esketamine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 12 May 2022 Data from this study was used to change in each symptom of depression and in symptomatic improvement pattern between placebo and antidepressant responses, published in the Psychiatry and Clinical Neurosciences.
- 21 Jan 2020 Status changed from active, no longer recruiting to completed.
- 04 Nov 2019 Status changed from recruiting to active, no longer recruiting.